Sarepta Therapeutics (SRPT) Accumulated Expenses (2010 - 2026)

Sarepta Therapeutics has reported Accumulated Expenses for 17 years, with the latest figure at $32.9 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 91.61% year-over-year to $32.9 million; the trailing twelve-month figure through Mar 2026 stood at $32.9 million (down 91.61% YoY), and the FY2025 full-year result was $359.7 million, up 294.71% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $32.9 million, down from $359.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $391.6 million in Q1 2025, with the low at $1.1 million in Q2 2022.
• Average Accumulated Expenses over 5 years is $143.9 million, with a median of $65.9 million recorded in 2022.
• Year-over-year, Accumulated Expenses tumbled 99.55% in 2022 and soared 9707.45% in 2024.
• Tracing SRPT's Accumulated Expenses over 5 years: stood at $65.9 million in 2022, then grew by 19.39% to $78.7 million in 2023, then rose by 15.73% to $91.1 million in 2024, then soared by 294.71% to $359.7 million in 2025, then slumped by 90.86% to $32.9 million in 2026.
• The last three Accumulated Expenses figures came in at $32.9 million (Q1 2026), $359.7 million (Q4 2025), and $295.8 million (Q3 2025), per Business Quant data.

Peer Comparison